Valuation : Larimar Therapeutics, Inc.

Market Cap 419M 361M 338M 309M 582M 40B 583M 4.01B 1.57B 20.19B 1.57B 1.54B 66.96B P/E 2026 *
-2.98x
P/E 2027 * -3.29x
Enterprise Value 331M 285M 267M 244M 460M 31.62B 461M 3.17B 1.24B 15.96B 1.24B 1.22B 52.93B EV / Sales 2026 *
-
EV / Sales 2027 * 6.72x
Free-Float
98.85%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Larimar Therapeutics, Inc.

1 day-0.99%
1 week-4.07%
Current month+4.97%
1 month+10.47%
3 months+15.23%
6 months-24.48%
Current year+5.25%
1 week 3.93
Extreme 3.93
4.24
1 month 3.72
Extreme 3.715
4.46
Current year 2.72
Extreme 2.715
6.42
1 year 2.72
Extreme 2.715
6.42
3 years 1.61
Extreme 1.61
13.68
5 years 1.53
Extreme 1.53
15.26
10 years 1.53
Extreme 1.53
25.87
Manager TitleAgeSince
Chief Executive Officer 67 01/05/2020
Director of Finance/CFO 67 28/05/2020
Chief Tech/Sci/R&D Officer 65 17/07/2023
Director TitleAgeSince
Director/Board Member 67 01/01/2020
Chairman 61 28/05/2020
Director/Board Member 58 28/05/2020
Date Insider Type Main position Quantity % Market Cap.
7/6/26 A Buy

Director

50,000 0.0584%
5/19/26 A Free

Director

55,150 0.0644%
5/19/26 A
Deerfield Management Co. LP
FreeCompany 55,150 0.0644%
Change 5-day change 1-year change 3-year change Capi.($)
-0.99%-4.07%+10.77%+1.78% 419M
-1.59%-3.35%+52.37%+93.70% 69.54B
-1.34%-0.75%+48.21%+91.86% 64.97B
+0.30%-0.69%+52.56%+10.23% 26.51B
-2.35%-5.75%-12.90%+448.54% 25.89B
-8.37%-12.43%+2.08%-16.71% 25.64B
-0.96%+10.36%+283.06%+436.50% 20.22B
-0.51%+0.23%+35.77%-18.70% 19.98B
-1.91%-4.37%+13.28%+535.19% 15.69B
-1.47%+0.68%+45.51%+143.08% 13.49B
Average -1.92%-2.14%+53.07%+172.55% 28.23B
Weighted average by Cap. -1.93%-1.51%+53.66%+151.29%

Financials

2026 *2027 *
Net sales - 41.7M 35.93M 33.69M 30.75M 57.94M 3.99B 58.12M 400M 156M 2.01B 157M 153M 6.67B
Net income -139M -119M -112M -102M -192M -13.24B -193M -1.33B -518M -6.68B -520M -509M -22.16B -158M -136M -128M -117M -220M -15.13B -221M -1.52B -592M -7.64B -595M -582M -25.33B
Net Debt -87.7M -75.57M -70.86M -64.68M -122M -8.38B -122M -841M -328M -4.23B -329M -322M -14.03B -138M -119M -112M -102M -192M -13.24B -193M -1.33B -518M -6.68B -520M -509M -22.16B
Logo Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
Employees
71
Date Price Change Volume
28/08/26 $4.010 -0.99% 641,505
27/08/26 $4.050 -2.88% 673,588
26/08/26 $4.170 +0.24% 702,135
25/08/26 $4.160 +2.72% 1,082,141
24/08/26 $4.050 -3.11% 945,554
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
4.010USD
Average target price
14.30USD
Spread / Average Target
+256.61%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LRMR Stock